One of the most important cardiovascular (CVS) liabilities in safety pharmacology is the life-threatening condition known as Torsades de pointes (TdP) which is principally mediated by changes in the activity of the hERG (Kv11.1) channel and other important cardiac ion channels (Cav1.2, Nav1.5, Kv4.3, Kir2.1 and Kv7.1). Many compounds can affect the activities of the ion channels or transporters, thus have the potential of delaying the ventricular repolarization and leading to prolonged QT interval.
https://acroscell.creative-bio....array.com/cardiac-io